US20170354592A1 - Parenteral sustained-release delivery of carvedilol disperse systems - Google Patents

Parenteral sustained-release delivery of carvedilol disperse systems Download PDF

Info

Publication number
US20170354592A1
US20170354592A1 US15/621,844 US201715621844A US2017354592A1 US 20170354592 A1 US20170354592 A1 US 20170354592A1 US 201715621844 A US201715621844 A US 201715621844A US 2017354592 A1 US2017354592 A1 US 2017354592A1
Authority
US
United States
Prior art keywords
carvedilol
composition
nanoparticles
microparticles
preferably less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/621,844
Other languages
English (en)
Inventor
Vera Ivanova
Kaoru Maeda
Wan Wang
Dongwei GUO
Jingjun Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASCENDIA PHARMACEUTICALS LLC
Original Assignee
ASCENDIA PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/621,844 priority Critical patent/US20170354592A1/en
Priority to JP2018565290A priority patent/JP2019521979A/ja
Priority to CN201780036949.9A priority patent/CN110381929A/zh
Priority to BR112018075984-8A priority patent/BR112018075984A2/pt
Priority to CA3027368A priority patent/CA3027368A1/fr
Priority to PCT/US2017/037311 priority patent/WO2017218576A1/fr
Application filed by ASCENDIA PHARMACEUTICALS LLC filed Critical ASCENDIA PHARMACEUTICALS LLC
Priority to KR1020197000045A priority patent/KR102474392B1/ko
Publication of US20170354592A1 publication Critical patent/US20170354592A1/en
Assigned to ASCENDIA PHARMACEUTICALS, LLC reassignment ASCENDIA PHARMACEUTICALS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUANG, JINGJUN, IVANOVA, VERA, MAEDA, KAORU, GUO, Dongwei, WANG, WAN
Priority to US16/429,693 priority patent/US10792244B2/en
Priority to JP2022081399A priority patent/JP2022103337A/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US15/621,844 2016-06-13 2017-06-13 Parenteral sustained-release delivery of carvedilol disperse systems Abandoned US20170354592A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2018565290A JP2019521979A (ja) 2016-06-13 2017-06-13 カルベジロール分散系の非経口徐放送達
CN201780036949.9A CN110381929A (zh) 2016-06-13 2017-06-13 卡维地洛分散系统的肠胃外缓释传递
BR112018075984-8A BR112018075984A2 (pt) 2016-06-13 2017-06-13 composição de distribuição de fármaco parenteral para liberação sustentada
CA3027368A CA3027368A1 (fr) 2016-06-13 2017-06-13 Administration a liberation prolongee par voie parenterale de systemes de dispersion de carvedilol
PCT/US2017/037311 WO2017218576A1 (fr) 2016-06-13 2017-06-13 Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol
US15/621,844 US20170354592A1 (en) 2016-06-13 2017-06-13 Parenteral sustained-release delivery of carvedilol disperse systems
KR1020197000045A KR102474392B1 (ko) 2016-06-13 2017-06-21 카르베딜롤 분산 시스템의 비경구 지속-방출 전달
US16/429,693 US10792244B2 (en) 2016-06-13 2019-06-03 Parenteral sustained-release delivery of carvedilol disperse systems
JP2022081399A JP2022103337A (ja) 2016-06-13 2022-05-18 カルベジロール分散系の非経口徐放送達

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349390P 2016-06-13 2016-06-13
US15/621,844 US20170354592A1 (en) 2016-06-13 2017-06-13 Parenteral sustained-release delivery of carvedilol disperse systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/429,693 Continuation US10792244B2 (en) 2016-06-13 2019-06-03 Parenteral sustained-release delivery of carvedilol disperse systems

Publications (1)

Publication Number Publication Date
US20170354592A1 true US20170354592A1 (en) 2017-12-14

Family

ID=60573487

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/621,844 Abandoned US20170354592A1 (en) 2016-06-13 2017-06-13 Parenteral sustained-release delivery of carvedilol disperse systems
US16/429,693 Active US10792244B2 (en) 2016-06-13 2019-06-03 Parenteral sustained-release delivery of carvedilol disperse systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/429,693 Active US10792244B2 (en) 2016-06-13 2019-06-03 Parenteral sustained-release delivery of carvedilol disperse systems

Country Status (8)

Country Link
US (2) US20170354592A1 (fr)
EP (1) EP3468539A4 (fr)
JP (2) JP2019521979A (fr)
KR (1) KR102474392B1 (fr)
CN (1) CN110381929A (fr)
BR (1) BR112018075984A2 (fr)
CA (1) CA3027368A1 (fr)
WO (1) WO2017218576A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063813A1 (fr) * 2019-10-01 2021-04-08 Evonik Operations Gmbh Procédé de préparation de nanoparticules sous forme de poudre comprenant un polyester biorésorbable
CN114159405A (zh) * 2020-09-10 2022-03-11 上海中医药大学 一种在胃肠道内稳定的口服纳米粒子及其制备方法和应用
CN115297849A (zh) * 2020-03-16 2022-11-04 株式会社理光 用于生产颗粒的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018075984A2 (pt) 2016-06-13 2019-04-02 Ascendia Pharmaceuticals, Llc composição de distribuição de fármaco parenteral para liberação sustentada

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
JP2002510045A (ja) * 1998-03-30 2002-04-02 バイオシャフ リミテッド 細胞および体液における一般的診断要因を分析するためのフロー式細胞数計算器
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
US6284763B1 (en) 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
DE60105996T2 (de) * 2000-04-03 2006-03-09 F. Hoffmann-La Roche Ag Konzentrierte lösungen von carvedilol
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
WO2003030818A2 (fr) * 2001-10-05 2003-04-17 Pichit Suvanprakorn Principes actifs vehicules par des perles de liposomes
AU2003287526A1 (en) 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
US20050143378A1 (en) 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
WO2006044694A2 (fr) 2004-10-15 2006-04-27 Palo Alto Investors Methodes et compositions destinees a traiter un etat pathologique chez un sujet
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
EP2756756B1 (fr) 2008-04-28 2016-01-06 Zogenix, Inc. Compositions inédites destinées au traitement de la migraine
ES2634669T3 (es) * 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
EP2680820B1 (fr) 2011-03-01 2022-11-02 2-BBB Medicines B.V. Chargement liposomal actif avancé de substances médiocrement solubles dans l'eau
ES2656091T3 (es) * 2012-07-27 2018-02-23 Izumi Technology, Llc. Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan
BR112018075984A2 (pt) 2016-06-13 2019-04-02 Ascendia Pharmaceuticals, Llc composição de distribuição de fármaco parenteral para liberação sustentada

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063813A1 (fr) * 2019-10-01 2021-04-08 Evonik Operations Gmbh Procédé de préparation de nanoparticules sous forme de poudre comprenant un polyester biorésorbable
CN114555064A (zh) * 2019-10-01 2022-05-27 赢创有限公司 制备包含生物可再吸收的聚酯的粉末形式的纳米颗粒的方法
US11964058B2 (en) * 2019-10-01 2024-04-23 Evonik Corporation Process for preparing nanoparticles in the form of a powder comprising a bio-resorbable polyester
CN115297849A (zh) * 2020-03-16 2022-11-04 株式会社理光 用于生产颗粒的方法
CN114159405A (zh) * 2020-09-10 2022-03-11 上海中医药大学 一种在胃肠道内稳定的口服纳米粒子及其制备方法和应用

Also Published As

Publication number Publication date
US10792244B2 (en) 2020-10-06
EP3468539A1 (fr) 2019-04-17
CA3027368A1 (fr) 2017-12-21
WO2017218576A1 (fr) 2017-12-21
KR20190109376A (ko) 2019-09-25
JP2019521979A (ja) 2019-08-08
BR112018075984A2 (pt) 2019-04-02
KR102474392B1 (ko) 2022-12-07
US20200000706A1 (en) 2020-01-02
EP3468539A4 (fr) 2020-01-15
CN110381929A (zh) 2019-10-25
JP2022103337A (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
US10792244B2 (en) Parenteral sustained-release delivery of carvedilol disperse systems
Tice et al. Parenteral drug delivery: injectables
US20030235619A1 (en) Polymer-lipid delivery vehicles
US20060177495A1 (en) Polymer-lipid delivery vehicles
S Duttagupta et al. Cubosomes: innovative nanostructures for drug delivery
US9907758B2 (en) Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins
RU2577683C2 (ru) Липосомная композиция и способ ее получения
NO333811B1 (no) Stealth-nanokapsler, fremgangsmåter for fremstilling derav og anvendelse som en bærer for aktivt prinsipp/aktive prinsipper
JP2001508445A (ja) 溶解性に劣る薬物のためのエマルジョンビヒクル
Zhang et al. A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics
US10772834B2 (en) Liposome composition and method for producing same
WO2023030524A1 (fr) Système d'administration de nanoporteurs de liposomes ciblant l'athérosclérose et son procédé de préparation
JP2004520398A (ja) 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
Mansour et al. Intranasal versus intraperitoneal Myrj 59-stabilized cubosomes: A potential armamentarium of effective anti-diabetic therapy
CN110035743A (zh) 一种Talazoparib药物组合物及其应用
US8859001B2 (en) Fenoldopam formulations and pro-drug derivatives
Agrawal et al. A review on parenteral controlled drug delivery system
CN1470289A (zh) 一种高分子纳米药物载体和制剂的制备方法
CN112888428A (zh) 包封亲脂和亲水性化合物的纳米胶囊包纳米胶囊型的多隔室体系及相关生产方法
CA3172776A1 (fr) Compositions pharmaceutiques d'un macrolide polyene therapeutique et leurs procedes d'utilisation
Sheikh et al. Advanced injectable drug delivery system: A brief review
Southern et al. Parenteral Drug Delivery: Injectables
Nikam et al. Available through Online Review Article www. ijptonline. com
dos Santos Matos Development of micro and nanostructured systems for cutaneous leishmaniasis treatment
Mali et al. REVIEW ON PARENTRAL DRUG DELIVERY SYSTEM: A NOVEL APPROACH

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

AS Assignment

Owner name: ASCENDIA PHARMACEUTICALS, LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IVANOVA, VERA;MAEDA, KAORU;WANG, WAN;AND OTHERS;SIGNING DATES FROM 20181207 TO 20181211;REEL/FRAME:047775/0269

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION